This editorial commentary critically appraises a retrospective single-center cohort study (Kim et al., 2026; n=211 children) asking whether early corticosteroid use for extrarenal IgA vasculitis (IgAV) symptoms alters the incidence, timing, or urinary phenotype of subsequent kidney involvement.
Kidney involvement occurred in 21.7% (20/92) of corticosteroid-treated children vs. 11.8% (14/119) of untreated children — a difference that did not reach statistical significance (p=0.054; OR 2.083, 95% CI 0.988–4.392). Time to kidney involvement was also not significantly different (1.03 vs. 0.72 months). The commentary concludes there is no evidence that symptom-driven corticosteroid exposure prevents or delays IgAV nephritis (IgAVN), and warns that the numerically higher event rate in treated children reflects confounding by indication (greater disease severity), not causation.
- Only 34 kidney events and a short median follow-up of 2.4 months (surveillance recommended ≥6 months) limit the study's ability to detect late-onset nephritis. - Confounding by indication is the principal flaw: corticosteroid-treated children had more GI involvement, arthralgia, and higher inflammatory markers. - Kidney biopsies were performed in only 3 children, so histologic activity cannot be related to corticosteroid exposure or urinary phenotype.
Prior corticosteroid use should never reduce vigilance for kidney disease: continue structured urinalysis and blood-pressure monitoring on the same schedule in all children, regardless of steroid exposure, for at least 6 months after each IgAV episode. When biopsy criteria are met (UPCR >2 mg/mg, eGFR <90, or persistent moderate/mild proteinuria), do not delay biopsy because proteinuria has improved — proceed with biopsy and supportive therapy in parallel.
